China is the bigger Epilepsy Drugs market: $772 Mn against $175 Mn in 2023, about 4.4 times as large.
India grows faster: 6.5% a year, against 5%. The gap still grows from $597 Mn to $929 Mn by 2033.
Clinical research: 52 active trials in China, 4 in India.
| Measure |  China |  India |
|---|---|---|
| Market size, 2023 | $772 Mn | $175 Mn |
| Market size, 2033 projected | $1.3 Bn | $328 Mn |
| Growth a year (CAGR) | 5% | 6.5% |
| Money added, 2023–2033 | $485 Mn | $153 Mn |
| Share of the world market | 8% | 1.8% |
| Size rank of 24 countries | #2 | #12 |
| Market per person, 2023 | $0.55 | $0.12 |
| Active clinical trials | 52 | 4 |
| Full report | China report | India report |
Year by year, 2023 to 2033
China India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Epilepsy Drugs, China or India?
China is the bigger Epilepsy Drugs market: $772 Mn against $175 Mn in 2023, about 4.4 times as large.
Which grows faster in Epilepsy Drugs, China or India?
India grows faster: 6.5% a year, against 5%. The gap still grows from $597 Mn to $929 Mn by 2033.
More Epilepsy Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.